diagnosis
Diagnosis should be made on the basis of radiological investigations (MRI and CT are both useful) and pathomorphological assessment according to the World Health Organization classification from a biopsy, fine-needle aspiration or biliary brush cytology. Final pathological diagnosis has to be obtained before any chemotherapy, radiotherapy or other non-surgical oncological therapy, but is not critical for planning surgery in patients with characteristic findings of resectable biliary cancer.
staging
Staging consists of complete history and physical examination, blood counts, liver function tests, chest X-ray, imaging of the abdomen by sonography and CT scan or MRI, endoscopic retrograde or percutaneous transhepatic cholangiography, and possibly endoscopic ultrasonography, cholangioscopy and laparoscopy. Upper and lower endoscopy has to be performed in patients with an isolated intrahepatic mass. The staging is to be given according to the TNM 2010 system separately for gallbladder cancer (Table 1) , intrahepatic cholangiocarcinoma (Table 2a) , perhilar cholangiocarcinoma (Table2b), and distal cholangiocarcinoma (Table2c). Hilar cholangiocarcinoma (Klatskin's Tumor) is clinically staged depending on the involvement of the hepatic ducts according to the BismuthCorlette classification, which is presented in Table 3 .
treatment after incidental finding of gallbladder cancer on pathological review
A radical re-resection (after a complete staging including laparoscopy demonstrating resectability) is highly recommended for patients with incidental gallbladder carcinoma stage T1b (tumour invades muscle layer) or greater. Patients with T1a tumours (tumour invades lamina propria) do not further benefit from re-resection if the gallbladder was removed intact and should be observed only [III, B] . treatment after incidental finding of gallbladder cancer at surgery After incidental finding of gallbladder cancer at surgery staging has to be performed intraoperatively and extended cholecystecomy including en bloc hepatic resection and lymphadenectomy with or without bile duct excision has to be considered depending on resectability and expertise of the surgeon.
treatment of resectable tumours
Complete surgical resection is the only potentially curative treatment available. Resection of gallbladder cancer consists of extended cholecystecomy including en bloc hepatic resection and lymphadenectomy (porta hepatis, gastrohepatic ligament, retroduodenal) with or without bile duct excision. Major hepatectomy including caudate lobectomy such as extended right lobe resection with portal vein resection increases resectability and radicality for stage 3 and 4 hilar cholangiocarcinomas and has been associated with higher 5-year survival rates [III, B] . Preoperative transartial or portal vein embolization increases the remnant liver volume in patients with estimated postresection volumes of <25% and appears to reduce postoperative liver dysfunction. Indication of biliary drainage should be systematically discussed with specialized surgeons before surgery.
Even in patients undergoing aggressive surgery 5-year survival rates are 5%-10% for gallbladder cancer and 10%-40% for cholangiocarcinoma.
adjuvant (and additive) therapy
Additive fluorouracil-based chemotherapy has been associated with a small survival benefit after noncurative resection of gallbladder cancer [II, B] . Postoperative treatment after noncurative resection of cholangiocarcinoma remains controversial, and both supportive care and palliative chemotherapy and/or radiotherapy may be taken into consideration.
As both gallbladder and biliary tract neoplasms present a high incidence of local failure after surgical resection reaching 52%, a locoregional adjuvant treatment may be considered. Several retrospective reports on adjuvant and recently also on neoadjuvant (chemo)radiotherapy suggest survival benefit in both gallbladder and biliary duct cancer and postoperative chemoirradiation may be considered as an option. Fluorouracil was mostly used for chemoradiotherapy in biliary cancers. Recently concomitant gemcitabine with or without oxaliplatin has shown feasibility with radiotherapy in this disease.
treatment of unresectable tumours
Palliation of jaundice can be accomplished by endoscopic or percutaneous stenting of the biliary tree or by operative biliaryenteric bypass. Urgent biliary drainage and broad-spectrum antibiotics are crucial in patients with cholangitis due to obstructive jaundice.
Palliative chemotherapy added to both quantity and quality of life in advanced biliary cancer in a single phase III study [II, B] , but the survival benefit for chemotherapy in general is not yet clearly established. Based on the results of a pooled analysis of predominantly phase II trials gemcitabine combined with platinum compounds could also be an acceptable chemotherapy modality, since this combination offered the highest rates of objective response and tumour control in advanced biliary cancer [III, B] . Very resently, results of a multicentre, randomized phase III trial, the UK ABC-02 trial Tumor confined to the bile duct histologically T2
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Annals of Oncology clinical practice guidelines evaluating gemcitabine with or without cisplatin in patients with advanced or metastatic biliary tract cancer demonstrated a clear survival advantage (hazard ratio 0.68, P = 0.002) for the combination of GemCis without added clinically significant toxicity, setting a new standard of care in this disease. In the case that cisplatin is not applicable oxaliplatin might be an option for combination with gemcitabine, as several phase II trials demonstrated antitumour activity and good tolerability of GemOx in biliary cancers. In the past, lacking randomized controlled trials and an accepted standard, 5-fluorouracil or gemcitabine was routinely used. Monotherapy with these agents should be considered in the case that gemcitabine combined with either cisplatin or oxaliplatin is not applicable. Limiting toxicity of cisplatin may be renal or neuronal toxicity, myelosuppression or ototoxicity, wheras sensory neuropathy may be limiting for oxaliplatin. Concurrent chemoirradiation is an additional therapeutic option. After years of fluorouracil-based chemoradiotherapy gemcitabine and oxaliplatin have demonstrated feasibility as concomitant chemotherapy (see adjuvant/additive therapy). High radiation doses delivered by use of brachytherapy boost using iridium-192 may improve local control of disease. Very recently, intensity-modulated radiotherapy (IMRT) was shown to allow safe dose escalation to much higher doses compared with 3D-conformal radiotherapy and in this the way for future trials to test the effect of radiotherapy in this disease as recently shown in a retrospective comparative trial. Neoadjuvant therapy is not a routine option in biliary cancers. However, if restaging in patients with locally advanced disease shows potentially resectable tumours, resection should be considered.
Liver transplantation is indicated under strict research protocols at selected centres, for patients with early stage cholangiocarcinoma and anatomically unresectable lesions, but this approach is experimental and should not be offered outside the scope of clinical trials. Data on photodynamic therapy are slightly more advanced. In cholangiocarcinoma photodynamic therapy after decompression of the biliary tree has been proved to induce survival benefit in two small randomized trials [II, B] . In patients with a large visible mass on radiographic studies the effect of photodynamic therapy may be limited and combination with chemotherapy may be considered although appropriate trials are lacking.
response evaluation
Response evaluation is recommended 3 months after photodynamic therapy by means of cholangiography during routine stent exchange and after two or three cycles (8-12 weeks) of chemotherapy by clinical evaluation, subjective symptom evaluation, blood tests and repeating the initially abnormal radiological or ultrasound examinations.
follow-up
There is no evidence that regular follow-up after initial therapy may influence the outcome. Follow-up visits after complete resection should be restricted to history and physical examination considering symptoms, nutrition and psychosocial problems. 
